Breast Cancer
Opinion
SABCS research changes practice
Dr. Alan P. Lyss reviews the studies from the San Antonio Breast Cancer Symposium that are likely to change practice immediately.
Conference Coverage
ctDNA shows clinical value in advanced breast cancer
SAN ANTONIO – The plasmaMATCH trial showed that gene level agreement between ctDNA results measured by digital PCR versus sequencing was as high...
Conference Coverage
Sensitivity of ctDNA equivalent to that of tumor tissue sequencing
SAN ANTONIO – When plasma and tumor tissue samples were taken within 60 days of one another, sensitivity of ctDNA testing was 98% for digital...
Conference Coverage
Neoadjuvant cisplatin fails to beat standard AC in HER2-negative breast cancer
SAN ANTONIO – Platinum-based chemotherapy was associated with an 18% pCR rate, compared with 26% for standard AC among newly diagnosed HER2-...
Conference Coverage
Chemotherapy better for metastatic breast cancer maintenance than durvalumab
Exploratory analyses showed that patients with triple-negative breast cancer and PD-L1-positive tumors might benefit from durvalumab maintenance...
Opinion
New evidence informs discussions on FL treatment and breast screening
Dr. Alan P. Lyss explores recent studies on rituximab maintenance in follicular lymphoma and the use of MRI as a supplemental screening for women...
Conference Coverage
Oral paclitaxel bests IV version for tumor response, neuropathy incidence in mBC
SAN ANTONIO – An oral formulation of paclitaxel given with the P-glycoprotein pump inhibitor encequidar improved...
Conference Coverage
PEARL lacks luster in metastatic breast cancer progressing on AIs
SAN ANTONIO – Palbociclib plus endocrine therapy was not superior to capecitabine in patients with HR-positive/HER2-...
Conference Coverage
TNBC: Weekly nab-paclitaxel delivers, denosumab disappoints
SAN ANTONIO - Among patients with TNBC who were treated with weekly nab-paclitaxel, 60.4% achieved pCR, compared with 50.0% who were treated with...
Conference Coverage
First report from NeoTRIPaPDL1: No pCR benefit with atezolizumab in TNBC
SAN ANTONIO – Adding atezolizumab, an anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, to neoadjuvant...
Conference Coverage
ctDNA, CTCs predict TNBC relapse – now what?
SAN ANTONIO – Liquid biopsy can identify patients with triple-negative breast cancer at high risk of relapse, but no...